Page 3 - Dominik Escher News Today : Breaking News, Live Updates & Top Stories | Vimarsana

22. April 2021, 08:58 Uhr
St. Peter Port, Guernsey / Küsnacht – Pureos Bioventures announces the final closing of its first fund BB Pureos Bioventures LP («Pureos») with a committed capital of USD 205 million. Pureos will exclusively invest in innovative private drug development companies with an emphasis on novel biological drugs and emerging modalities such as nucleic acid, cell- and gene therapies. The fund’s portfolio companies are built on scientific excellence with strong teams to develop therapies across a broad spectrum of indications including oncology, immunology, ophthalmology, rare diseases and neuroscience. The fund invests globally, with a primary focus on Switzerland and Europe. The Pureos team consists of experienced venture capitalists, biotech entrepreneurs and drug developers. With its committed capital, Pureos is the largest institutional Swiss VC fund that solely invests in private biotech companies. ....

Dominik Escher , Anja Harmeier , Pureos Bioventures , Klaus Breiner , River Renal Corp , Peter Port , Alentis Therapeutics , Corlieve Therapeutics , Imcheck Therapeutics , Lava Therapeutics , Novago Therapeutics , Vico Therapeutics , Bellevue Asset , டோமினிக் எஶர் , கிளாஸ் ப்ரெய்னர் , பீட்டர் போர்த் , லாவா சிகிச்சை , விக்கோ சிகிச்சை , பெல்வ்யூ சொத்து ,